6-K - Nasus Pharma Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Nasus Pharma Ltd. announced positive top-line results from its Phase 2 clinical study of NS002 intranasal epinephrine powder, achieving significantly faster time to 100 pg/mL therapeutic threshold (median 1.69 minutes vs 3.42 minutes for EpiPen®, p=0.033) and higher early absorption. The company plans to initiate a pivotal study in Q4 2026.

Key Takeaways

1NS002 median T100 of 1.69 minutes vs 3.42 minutes for EpiPen® (p=0.033)

2At 5 minutes, 88.4% NS002 subjects reached threshold vs 64.6% EpiPen® (p=0.0081)

3NS002 Tmax median 15 minutes vs 19.8 minutes EpiPen®

450% higher epinephrine absorption in first 10 minutes with NS002

5No serious adverse events reported for NS002

6Pivotal study initiation planned for Q4 2026

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (3)

6-K

99.1

EX-99.1

99.2

EX-99.2